About

Axcelead Drug Discovery Partners is an integrated solutions provider in drug discovery and non-clinical research. We are uniquely positioned having carved out a Preclinical R&D Discovery Unit from Takeda Pharmaceuticals. We preserved the talent, the tools, the Pharma origin compound library and Legacy Data under the same roof. Our scientific team is pioneering disruptive and differentiated discovery solutions for diseases with high unmet needs. Axcelead’s integrated solution span the drug discovery continuum from early-stage exploration studies to candidate optimization and even a bridge process to clinical development. For example, hit identification service using pharma origin, huge, high-quality, and diverse compound library has more than 700 cases for multiple target classes with more than 90% hit rates. In the stage of lead generation/optimization, if your target of interest is in our legacy data, you can obtain a powerful jump start toward candidate selection. Legacy data, deep knowledge & extensive experience of the target enable generation of a high-quality candidate in the shortest approach. Our exceptional discovery engine improves success rates for your drug discovery campaigns. About Axcelead Drug Discovery Partners, Inc. Axcelead Drug Discovery Partners Inc. is an integrated drug discovery and development solution provider, serving biotechnology and pharmaceutical companies all over the world. Our well-experienced team works closely with you for every step of your drug discovery project, from target identification, hit identification/characterization, lead generation/optimization, candidate selection, to IND enabling and beyond. About Axcelead Drug Discovery Partners, Inc. Axcelead Drug Discovery Partners Inc. is an integrated drug discovery and development solution provider, serving biotechnology and pharmaceutical companies all over the world. Our well-experienced team works closely with you for every step of your drug discovery project, from target identification, hit identification/characterization, lead generation/optimization, candidate selection, to IND enabling and beyond. Axcelead is a healthcare platform company that owns Axcelead Drug Discovery Partners, a Japan-based global drug discovery solution provider, and ARCALIS, a CDMO company capable of integrated manufacturing of mRNA pharmaceuticals. Axcelead Drug Discovery Partners offers integrated drug discovery services from target identification to IND enabling studies. With a mission to accelerate research as your drug discovery engine, Axcelead Drug Discovery Partners provides exceptional expertise, flexible partnerships, and access to valuable legacy data. We are uniquely positioned having carved out a Preclinical R&D Discovery Unit from Takeda Pharmaceuticals. Axcelead Drug Discovery Partners (ADDP) is a Japan-based global provider of drug discovery solutions, established in 2017 as a spin-out from Takeda Pharmaceuticals. Our Drug Discovery Service offers a fully integrated, end-to-end approach, seamlessly connects all functions to advance drug discovery programs from target validation to IND enabling studies in wide-range therapeutic areas, including neuroscience, oncology, cardiovascular, metabolic diseases, immunology & inflammation, and musculoskeletal disorders. Leveraging legacy data from over 1,000 research projects inherited from Takeda—including hit and lead compounds as well as extensive biological datasets— we help clients accelerate progress and achieve success with their drug discovery programs. In addition to Drug Discovery service, each of our core technology platforms is also available as a standalone service, allowing clients to access specialized capabilities as needed: • Hit identification through high-throughput screening using our proprietary compound library • Proprietary in silico design tools supporting medicinal chemistry design and optimization • Validated in vivo and in vitro pharmacology evaluations delivering translational insights • Comprehensive DMPK, safety assessment, and bioanalysis capabilities • Expertise across multiple modalities, including small molecules, peptides, oligonucleotides, mRNA-targeted therapies, protein degraders, ADCs, and regenerative medicine This flexible model ensures that our clients benefit from world-class science—whether as part of a fully integrated program or by engaging individual, best-in-class services tailored to their specific needs.